Protara Therapeutics (TARA) Accounts Payables (2013 - 2026)

Protara Therapeutics' Accounts Payables history runs 14 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 74.5% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 74.5% YoY), while the FY2025 annual figure was $3.5 million, down 21.7% from the prior year.
• Accounts Payables was $4.0 million for Q1 2026 at Protara Therapeutics, up from $3.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.3 million in Q2 2025 to a low of $392000.0 in Q2 2022.
• Historically, Accounts Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 654.34% in 2023, then slumped 76.18% in 2024.
• A 5-year view of Accounts Payables shows it stood at $1.6 million in 2022, then soared by 53.47% to $2.4 million in 2023, then soared by 81.96% to $4.4 million in 2024, then decreased by 21.7% to $3.5 million in 2025, then increased by 16.23% to $4.0 million in 2026.
• The last three Accounts Payables figures came in at $4.0 million (Q1 2026), $3.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.